Ask AI
ProCE Banner Activity

What I Wish I’d Known Before Starting Bispecific Antibody Therapy for Multiple Myeloma: A Patient Resource

PDF

Provide this resource to your patients with multiple myeloma who are considering or receiving bispecific antibody therapy with key questions from experienced patients that will help them better understand their treatment and what to expect.

Released: November 20, 2025

Share

Provided by

Provided by Clinical Care Options, LLC. in partnership with Smart Patients.

ProCE Banner

Supporters

Supported by an educational grant from Pfizer Inc.

Pfizer Inc.

Partners

Smart Patients

ProCE Banner

Target Audience

This activity is intended for hematologists/oncologists, oncology nurses and nurse practitioners, physician assistants, pharmacists and other healthcare professionals involved in the care and treatment of patients with RRMM.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Interpret pivotal clinical trial data on BCMA bispecific antibodies, including efficacy, safety, and use in earlier lines of therapy

  • Apply evidence-based strategies to initiate BCMA BsAb therapy and monitor for key adverse events (eg, CRS, ICANS, infections) across diverse practice settings

  • Design multidisciplinary care coordination strategies to support therapy adherence and treatment continuation in patients transitioning from academic to community settings

  • Integrate patient education and shared decision-making tools to align treatment with patient goals and improve persistence

Disclosure

Primary Author

Charise Gleason, MSN, NP-C, AOCNP, has no relevant financial relationships to disclose.